To determine the efficacy of this technology, we assayed CSF microvesicles from patients with glioma tumors, which had been typed for a dominant mutation (G395A) in the isocitrate dehydrogenase (IDH1) gene. This evidence concerns the gene IDH1 and central nervous system cancer.